Get started
Author

Laura Bouché

Observed names: Bouche, L, Bouche, Laura, L. Bouche, Laura Bouche
ORCID: 0009-0002-5519-5266
Observed ORCID: 0009-0002-5519-5266
OpenAlex ID: A5008901926
Mapping the complete glycoproteome of virion-derived HIV-1 gp120 provides insights into broadly neutralizing antibody binding
2016 · Maria Panico, Laura Bouché, et al. · Scientific Reports · 79
PDF
Loss of α2-6 sialylation promotes the transformation of synovial fibroblasts into a pro-inflammatory phenotype in arthritis
2021 · Yilin Wang, Aneesah Khan, et al. · Nature Communications · 62
PDF
Role of Glycosyltransferases Modifying Type B Flagellin of Emerging Hypervirulent Clostridium difficile Lineages and Their Impact on Motility and Biofilm Formation
2016 · Esmeralda Valiente, Laura Bouché, et al. · Journal of Biological Chemistry · 56
PDF
Gp120 on HIV-1 Virions Lacks O-Linked Carbohydrate
2015 · Elizabeth Stansell, Maria Panico, et al. · PLoS ONE · 32
PDF
A Single Synonymous Variant (c.354G>A [p.P118P]) in ADAMTS13 Confers Enhanced Specific Activity
2019 · Ryan Hunt, Gaya Hettiarachchi, et al. · International Journal of Molecular Sciences · 24
PDF
The S-layer protein of a Clostridium difficile SLCT-11 strain displays a complex glycan required for normal cell growth and morphology
2018 · Emma Richards, Laura Bouché, et al. · Journal of Biological Chemistry · 22
PDF
The Type B Flagellin of Hypervirulent Clostridium difficile Is Modified with Novel Sulfonated Peptidylamido-glycans
2016 · Laura Bouché, Maria Panico, et al. · Journal of Biological Chemistry · 18
PDF
Anti-HER2, High-DAR Antibody Fragment–Drug Conjugates with a Glucuronide-Based MMAE Linker–Payload Demonstrate Superior Efficacy over IgG-Based ADCs
2025 · Ioanna Stamati, Gokhan Yahioglu, et al. · Molecular Cancer Therapeutics · 5
Decreased fucosylation impacts epithelial integrity and increases risk for COPD
2023 · Carter Swaby, Bonnie Yeung-Luk, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 5
PDF
Abstract 909: Antibody fragment drug-conjugates (FDCs)-application of ANT-043 and ANT-045 in solid tumors
2021 · Mahendra P. Deonarain, Gokhan Yahioglu, et al. · Cancer Research · 3
Abstract 2901: Gastric cancer antibody fragment drug-conjugates (FDCs): From concept to clinical development
2020 · Mahendra P. Deonarain, Gokhan Yahioglu, et al. · Cancer Research · 2
Abstract 4399: ANT045: A novel format, antibody fragment drug-conjugate (FDC) product for challenging cMET-expressing solid tumors
2026 · Mahendra Deonarain, Bryan Edwards, et al. · Cancer Research
Abstract 2408: ADCs in cancer treatment: SPR-driven insights into discovery and characterization.
2026 · Soraya Diez-Posada, Cynthia Shuman, et al. · Cancer Research
Supplementary Figure 4 from Anti-HER2, High-DAR Antibody Fragment–Drug Conjugates with a Glucuronide-Based MMAE Linker–Payload Demonstrate Superior Efficacy over IgG-Based ADCs
2025 · Ioanna Stamati, Gokhan Yahioglu, et al.
PDF
Supplementary Data from Anti-HER2, High-DAR Antibody Fragment–Drug Conjugates with a Glucuronide-Based MMAE Linker–Payload Demonstrate Superior Efficacy over IgG-Based ADCs
2025 · Ioanna Stamati, Gokhan Yahioglu, et al.
Supplementary Figure 1 from Anti-HER2, High-DAR Antibody Fragment–Drug Conjugates with a Glucuronide-Based MMAE Linker–Payload Demonstrate Superior Efficacy over IgG-Based ADCs
2025 · Ioanna Stamati, Gokhan Yahioglu, et al.
PDF
Supplementary Figure 9 from Anti-HER2, High-DAR Antibody Fragment–Drug Conjugates with a Glucuronide-Based MMAE Linker–Payload Demonstrate Superior Efficacy over IgG-Based ADCs
2025 · Ioanna Stamati, Gokhan Yahioglu, et al.
PDF
Supplementary Table 2 from Anti-HER2, High-DAR Antibody Fragment–Drug Conjugates with a Glucuronide-Based MMAE Linker–Payload Demonstrate Superior Efficacy over IgG-Based ADCs
2025 · Ioanna Stamati, Gokhan Yahioglu, et al.
Supplementary Table 4 from Anti-HER2, High-DAR Antibody Fragment–Drug Conjugates with a Glucuronide-Based MMAE Linker–Payload Demonstrate Superior Efficacy over IgG-Based ADCs
2025 · Ioanna Stamati, Gokhan Yahioglu, et al.
Supplementary Table 1 from Anti-HER2, High-DAR Antibody Fragment–Drug Conjugates with a Glucuronide-Based MMAE Linker–Payload Demonstrate Superior Efficacy over IgG-Based ADCs
2025 · Ioanna Stamati, Gokhan Yahioglu, et al.
Supplementary Figure 2 from Anti-HER2, High-DAR Antibody Fragment–Drug Conjugates with a Glucuronide-Based MMAE Linker–Payload Demonstrate Superior Efficacy over IgG-Based ADCs
2025 · Ioanna Stamati, Gokhan Yahioglu, et al.
Supplementary Figure 3 from Anti-HER2, High-DAR Antibody Fragment–Drug Conjugates with a Glucuronide-Based MMAE Linker–Payload Demonstrate Superior Efficacy over IgG-Based ADCs
2025 · Ioanna Stamati, Gokhan Yahioglu, et al.
PDF
Supplementary Figure 7 from Anti-HER2, High-DAR Antibody Fragment–Drug Conjugates with a Glucuronide-Based MMAE Linker–Payload Demonstrate Superior Efficacy over IgG-Based ADCs
2025 · Ioanna Stamati, Gokhan Yahioglu, et al.
PDF
Supplementary Figure 5 from Anti-HER2, High-DAR Antibody Fragment–Drug Conjugates with a Glucuronide-Based MMAE Linker–Payload Demonstrate Superior Efficacy over IgG-Based ADCs
2025 · Ioanna Stamati, Gokhan Yahioglu, et al.
PDF
Supplementary Figure 10 from Anti-HER2, High-DAR Antibody Fragment–Drug Conjugates with a Glucuronide-Based MMAE Linker–Payload Demonstrate Superior Efficacy over IgG-Based ADCs
2025 · Ioanna Stamati, Gokhan Yahioglu, et al.
PDF
Works count: 37
Citation count: 308
H-index: 7
I10-index: 7
Year
Topic
Type